HI
ALXN

HBK Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

HBK Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,600,000
Closed -$1.21B – 977
2021
Q2 		$1.21B Buy
6,600,000
+875,000
+15% +$150M 4.25% 3
2021
Q1 		$875M Buy
5,725,000
+4,001,425
+232% +$619M 3.96% 3
2020
Q4 		$269M Buy
+1,723,575
New +$221M 1.76% 11
2019
Q2 		– Sell
-1,948
Closed -$263K – 1166
2019
Q1 		$263K Sell
1,948
-148,757
-99% -$18.5M ﹤0.01% 941
2018
Q4 		$14.7M Buy
+150,705
New +$17.8M 0.16% 100
2018
Q3 		– Sell
-29,869
Closed -$3.71M – 1410
2018
Q2 		$3.71M Sell
29,869
-45,171
-60% -$5.28M 0.02% 332
2018
Q1 		$8.36M Buy
75,040
+72,421
+2,765% +$8.66M 0.06% 178
2017
Q4 		$313K Buy
+2,619
New +$319K ﹤0.01% 844
2016
Q3 		– Sell
-2,052
Closed -$240K – 1069
2016
Q2 		$240K Buy
+2,052
New +$291K ﹤0.01% 890
2015
Q2 		– Sell
-65,600
Closed -$11.4M – 1156
2015
Q1 		$11.4M Sell
65,600
-24,120
-27% -$4.37M 0.11% 122
2014
Q4 		$16.6M Buy
89,720
+72,672
+426% +$13.5M 0.2% 81
2014
Q3 		$2.83M Sell
17,048
-89,652
-84% -$14.7M 0.04% 302
2014
Q2 		$16.7M Sell
106,700
-20,800
-16% -$3.28M 0.34% 54
2014
Q1 		$19.4M Buy
127,500
+108,600
+575% +$17.3M 0.36% 47
2013
Q4 		$2.52M Buy
18,900
+16,900
+845% +$2.03M 0.05% 255
2013
Q3 		$232K Sell
2,000
-34,282
-94% -$3.76M ﹤0.01% 807
2013
Q2 		$3.35M Buy
+36,282
New +$3.5M 0.05% 195

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

HBK Investments's ALXN Position: Q3 2021 in Review

HBK Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,600,000 shares — an estimated $1.21B sold.

HBK Investments first reported a position in ALXN in Q2 2013 and held it in 17 quarters. The position peaked at $1.21B in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • HBK Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • HBK Investments sold 6,600,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.21B.
  • HBK Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • HBK Investments's Alexion Pharmaceuticals position peaked at $1.21B in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on HBK Investments's 13F filing for Q3 2021, filed 15 Nov 2021.